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Biomarker research does not exist in isolation. Its usefulness can only be realized when it is
translated into prevention strategies to protect public health. In the context of air toxics, these
prevention strategies begin with the development of regulatory standards derived from risk
assessment schemes. The Clean Air Act Amendments of 1990 list 189 air toxics, including many
volatile organics, metals, and pesticides. The National Institute of Environmental Health Sciences
(NIEHS), through its affiliation with the National Toxicology Program, has generated toxicity and
carcinogenicity data on more than 100 of these air toxics. The NIEHS extramural and intramural
research portfolios support a variety of projects that develop and validate biomarkers for use in
environmental health science and risk assessment. Biomarkers have a tremendous potential in
the areas of regulating air toxics and protecting public health. Risk assessors need data provided
by biomarkers of exposure, biomarkers of dose/pharmacokinetics, biomarkers of susceptibility or
individual variability, and biomarkers of effects. The greatest benefit would be realized if biomarkers
could be employed in four areas of primary and secondary prevention. The first is the use of
biomarkers to enhance extrapolation of animal data to human exposure situations in establishing
risk standards. The second is the use of biomarkers that assess noncancer, as well as cancer,
end points. Important health end points include pulmonary dysfunction, immunotoxicity, and
neurotoxicity. Third, biomarkers that serve as early warning signs to detect intermediate effects
would enhance our ability to design timely and cost-effective intervention strategies. Finally,
biomarkers used to evaluate the effectiveness of intervention strategies, both in clinical and
regulatory settings, would enable us to ensure that programs designed to protect public health do,
in fact, achieve the desired outcome. Environ Health Perspect 104(Suppl 5):857-860 (1996)
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Introduction
Modern technology has greatly enhanced
our quality oflife. Pesticides have expanded
our agricultural capacity, transportation
systems allow us tremendous mobility, and
plastics have transformed our homes and
workplace. The technologies and industries
that have allowed this progress, however,
have also led to some unwanted and unin-
tended side effects. One such side effect is
the deterioration ofthe air we breathe.
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Environmental ethics have changed
since the early days of the Industrial
Revolution, when certain detrimental
changes in the quality of the environment
were accepted as unavoidable costs of
progress. Today, we realize that the rela-
tionship between humans and the environ-
ment is both dynamic and fragile and that
our lives depend on the health ofthe envi-
ronment. This realization has led to
increased contentiousness between propo-
nents of development and those for
conservation, and between issues of indus-
trialization and of environmental public
health. In the context of air pollution,
these difficulties and conflicts arise in large
measure from two important facts.
The first of these is that there are gaps
and uncertainties both in the databases
used to define adverse environmental
effects and in the extrapolation techniques
used to generate risk estimates based on
laboratory data. Filling these gaps and
resolving these uncertainties is paramount
if we are to more rationally manage the
economic benefits to be derived from
modern technology in ways that preserve
quality of life and sustainability of that
quality into the future.
The second cause for conflict is that the
adverse effects ofair pollution are not equi-
tably distributed. Air pollution moves, so
an area can suffer from air pollution prob-
lems not of its own creation. Additionally,
not everyone is equally susceptible to
health effects related to air pollution. The
elderly, the very young, the poor, and those
in poor health can be more vulnerable to
adverse effects related to poor air quality.
For these reasons, resolving air pollution
problems is more amenable to group or
regulatory action than to individual action.
Regulatory History
In the United States, the first attempts to
control air quality in urban settings date to
smoke emission control regulation passed
by Chicago and Cincinnati in the 1880s
and Pittsburgh and New York in the 1890s
(1). Smog-related air pollution and its
association with automobile exhaust began
to be recognized in the early 1940s.
California was the first state to adopt air
pollution laws with passage of the Air
Pollution Control Act of 1947 (1).
For most of this century, resolution of
air pollution problems was seen as a local,
rather than a federal, responsibility. Even
with passage of the first federal air quality
law, the Air Pollution Control Act of 1955,
the federal role was to generate information
and support research rather than to regu-
late. The political environment slowly
changed, however, and regulation of air
quality as we know it began in 1970 with
the establishment of the Environmental
Protection Agency (U.S. EPA) and the
1970 Clean Air Act Amendments, which
advocated a stronger regulatory role for the
federal government (1)*.
The 1970 Clean Air Act Amendments
established two types of air pollutants for
regulatory purposes. The first ofthese were
the criteria air pollutants that had been
*The Clean Air Act and its amendments focus on outdoor air
quality. There is no single act covering indoor air quality,
although the Occupational Safety and Health Administration
addresses indoor air quality issues in occupational settings, and
the U.S. EPA conducts risk assessments on air quality issues
such as radon and second-hand smoke. Indoor air quality is of
increasing concern; the U.S. Department of Labor estimates that
up to 30% of U.S. office buildings have indoor air quality prob-
lems (2). Several of the air toxics listed in the 1990 Clean Air Act
Amendments, such as formaldehyde and asbestos, are implicated
in indoor air quality problems.
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named in previous amendments. These six
pollutants-ozone, carbon monoxide,
particulate matter, sulfur dioxide, nitrogen
dioxide, and lead-are common through-
out the United States. National Ambient
Air Quality Standards have been set for
each and serve as a basis for determining
whether or not an area is in compliance
with the nation's air quality program. The
criteria air pollutants are widely distributed
throughout the country and are a demon-
strated hazard both to human health and
to the health ofthe ecosystem. It is because
of this broad distribution that they were
selected for use as national measures of air
quality. There are other air pollutants,
however, that are also hazardous to health
and to the environment, although their
composition tends to be more regional
rather than reflective of the country as a
whole. These hazardous air pollutants, or
air toxics, can be released from small sta-
tionary sources such as dry cleaners and
auto paint shops, from large stationary
sources such as chemical factories, and
from mobile sources such as automobile
exhaust (3). The 1970 Clean Air Act
Amendments authorized the U.S. EPA to
regulate air toxics and specifically called
for action on mercury, beryllium, and
asbestos (1).
In the intervening 20 years between
1970 and the 1990 Clean Air Act
Amendments, regulation under the criteria
air pollutant program helped achieve the
improvement in air quality that we enjoy
today, although ozone, carbon monoxide,
and particulate matter are still widespread
problems (4). The air toxics program, how-
ever, was less successful. Standards were set
on only seven ofthe many potential air tox-
ics: arsenic, asbestos, benzene, beryllium,
mercury, radionuclides, and vinyl chloride.
It was this failure to regulate the bulk ofair
toxics that persuaded Congress to try a dif-
ferent approach in 1990.
Under the 1990 Clean Air Act
Amendments, the Congress listed 189 sub-
stances presumed to merit the label "air
toxic." About half of these substances are
volatile organics, including benzene, car-
bon tetrachloride, butadiene, tetra-
chloroethylene, and xylene. Various metals
also figure prominently in the list as do a
number ofpesticides. Although the list is
subject to change, to date the only changes
made are that hydrogen sulfide has been
removed from the list and the glycol ethers
have been more completely listed by CAS
number. The current list of air toxics is
given in Table 1.
In these amendments, the Congress
directed the U.S. EPA to regulate based on
what was technologically possible. In the
terminology of the 1990 Clean Air Act
Amendments, industry should use the
maximum achievable control technology
(MACT). The 1990 Clean Air Act
Amendments acknowledge, however, that
employment ofthe "best available technol-
ogy" might still present residual risk to
exposed populations or subpopulations.
Therefore, the U.S. EPA, after identifying
the categories of air toxic emissions and
setting MACT standards for each category,
must examine the need for additional stan-
dards that address the issue ofresidual risk.
For carcinogens the acceptable risk level
would be 10- (5).
Current Database
Animal bioassays remain the backbone of
most risk assessment determinations.
Probably the most extensive database of
high-quality animal testing in the world is
that generated by the National Toxicology
Program (NTP). The NTP is a unique
national resource because not only are
studies conducted in a consistent and
tightly controlled manner, but all data
material, including slides, blocks, and wet
tissues, are archived and available for fur-
ther examination. Additionally, beginning
in 1987, the NTP began saving tissue from
all animal tumors found in chronic bio-
assays. This material is frozen and archived
so that, as important oncogenes and
tumor-suppressor genes are identified, these
tissues can be recovered and data results
reinterpreted in light ofnew information.
The NTP also recognizes the value of
mechanistic data. In the past, chemical dis-
position and pharmacokinetic data were
generated on a number of studies under
test. This effort has now become routine,
and the majority of 2-year bioassays
include pharmacokinetic, mechanistic, and
dosimetric studies.
Ofthe 189 air toxics listed in the 1990
Clean Air Act Amendments, more than
100 have been studied by the NTP. As
shown in Table 2, about 70% ofthe com-
pounds studied in short-term tests were
also studied in long-term, chronic tests;
23% of those studied in chronic assays
were conducted by the inhalation route of
exposure. Chemical disposition informa-
tion has been generated on 61 compounds
listed as air toxics and NTP-conducted
genetic toxicity assay on 195 air toxic com-
pounds. (The number exceeds the list of
189 air toxics because the 1990 Clean Air
Act Amendments employed categories of
compounds, such as the glycol ethers,
which incorporate many separate com-
pounds for study.) Ninety-two air toxic
compounds have been studied in some
type of organ system assay. These assays
include measures of teratology, reproduc-
tive function, neurotoxicity, and immuno-
toxicity. Clearly the NTP database makes a
significant contribution to our knowledge
ofair toxics and will figure prominently in
future risk assessment determinations.
Potential of Biomarkers
in Risk Assessment
As mentioned in the Introduction, con-
flicts over managing air quality arise not
only from gaps in the database, but also
from uncertainties inherent in extrapolating
from existing data sets to actual exposure
situations. Moving toward a health-based
regulatory approach for air toxics will
require a tremendous improvement in
the science of toxicology. It will require
better ability to assess exposures and an
understanding of mechanisms of disease
causation, of pharmacokinetics, of dose-
response relationships, and of individual
differences in susceptibility. The National
Academy ofSciences, in its report assessing
current risk assessment methodology, envi-
sions moving toward a regulatory environ-
ment in which biologic measures that
reflect human exposure situations will
replace default assumptions that ignore
human variability or introduce conserva-
tive measures to avoid it (6). Enhancing
our ability to achieve this worthwhile goal
clearly resides within the purview of bio-
marker research. The literature already
contains promising results on the potential
ofthis technology in air toxics research.
For example, Perera et al. (7) used bio-
logic indicators to establish a link between
environmental air pollution and molecular
and genetic damage in humans. These
studies compared populations in areas of
Poland with highly polluted air with those
living in relatively unpolluted rural areas.
They found that living in areas ofhighly
polluted air was associated with significant
increases in carcinogen-DNA adducts, sis-
ter chromatid exchange, chromosomal
aberrations, and ras gene overexpression.
Other investigators have been attempting
to understand DNA-protein cross-linking
by metals, the role of this cross-linking in
carcinogenesis and toxicity, and the poten-
tial ofcross-linking as a biomarker ofexpo-
sure and effect. It is known that chromium
and nickel induce DNA-protein cross-links
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Table 1. Air Toxics, 1990 Clean AirAct.
CAS no. Chemical name CAS no. Chemical name CAS no. Chemical name
75070 Acetaldehyde
60355 Acetamide
75058 Acetonitrile
98862 Acetophenone
53963 2-Acetylaminofluorene
107028 Acrolein
79061 Acrylamide
79107 Acrylic acid
107131 Acrylonitrile
107051 Allyl chloride
92671 4-Aminobiphenyl
62533 Aniline
90040 o-Anisidine
1332214 Asbestos
71432 Benzene (including benzene from
gasoline)
92875 Benzidine
98077 Benzotrichloride
100447 Benzyl chloride
92524 Biphenyl
117817 Bis(2-ethylhexyl)phthalate
542881 Bis(chloromethyl)ether
75252 Bromoform
106990 1,3-Butadiene
156627 Calcium cyanamide
105602 Caprolactam
133062 Captan
63252 Carbaryl
75150 Carbon disulfide
56235 Carbon tetrachloride
463581 Carbonyl sulfide
120809 Catchall
133904 Chloramben
57749 Chlordane
7782505 Chlorine
79118 Chloroacetic acid
532274 2-Chloroacetophenone
108907 Chlorobenzene
510156 Chlorobenzilate
67663 Chloroform
107302 Chloromethyl methyl ether
126998 Chloroprene
1319773 Cresols/cresylic acid (isomers and
mixture)
95487 o-Cresol
108394 m-Cresol
106445 p-Cresol
98828 Cumene
94757 2,4-Dichlorophenoxyacetic acid, salts
and esters
3547044 1,1-Dichloro-2,2-bis(p-chlorophenyl)
ethylene
334883 Diazomethane
132649 Dibenzofurans
96128 1,2-Dibromo-3-chloropropane
84742 Dibutylphthalate
106467 1,4-Dichlorobenzene
91941 3,3-Dichlorobenzidene
111444 Dichloroethyl ether(bis(2-
chloroethyl)ether)
542756 1,3-Dichloropropene
62737 Dichlorvos
111422 Diethanolamine
121697 N,N-Diethylaniline (N,N-dimethylaniline)
64675 Diethyl sulfate
119904 3,3-Dimethoxybenzidine
60117 Dimethylaminoazobenzene
119937
79447
68122
57147
131113
77781
534521
51285
121142
123911
122667
106898
106887
140885
100414
51796
75003
106934
107062
107211
151564
75218
96457
75343
50000
76448
118741
87683
77474
67721
822060
680319
110543
302012
7647010
7664393
123319
78591
58899
108316
67561
72435
74839
74873
71556
78933
60344
74884
108101
624839
80626
1634044
101144
75092
101688
101779
91203
98953
92933
100027
79469
684935
62759
59892
56382
3,3'-Dimethylbenzidine
Dimethylcarbamoyl chloride
Dimethyl formamide
11,1-Dimethylhydrazine
Dimethylphthalate
Dimethyl sulfate
4,6-Dinitro-o-cresol, and salts
2,4-Dinitrophenol
2,4-Dinitrotoluene
1,4-Dioxane (1,4-diethyleneoxide)
1,2-Diphenylhydrazine
Epichlorohydrin (1-chloro-2,3-
epoxypropane)
1,2-Epoxybutane
Ethyl acrylate
Ethyl benzene
Ethyl carbamate (urethane)
Ethyl chloride (chloroethane)
Ethylene dibromide (dibromoethane)
Ethylene dichloride (1,2-dichloroethane)
Ethylene glycol
Ethylene imine (aziridine)
Ethylene oxide
Ethylene thiourea
Ethylidene dichloride (1,1 -dichloroethane)
Formaldehyde
Heptachlor
Hexachlorobenzene
Hexachlorobutadiene
Hexachlorocyclopentadiene
Hexachloroethane
Hexamethylene-1,6-diisocyanate
Hexamethylphosphoramide
Hexane
Hydrazine
Hydrochloric acid
Hydrogen fluoride (hydrofluoric acid)
Hydroquinone
Isophorone
Lindane (all isomers)
Maleic anhydride
Methanol
Methoxychlor
Methyl bromide (bromomethane)
Methyl chloride (chloromethane)
Methyl chloroform (1,1,1-
trichloroethane)
Methyl ethyl ketone (2-butanone)
Methyl hydrazine
Methyl iodide (lodomethane)
Methyl isobutyl ketone (hexone)
Methyl isocyanate
Methyl methacrylate
Methyl tert-butyl ether
4,4-Methylenebis (2-chloroaniline)
Methylene chloride (dichloromethane)
Methylene diphenyl diisocyante
4,4'-Methylenedianiline
Naphthalene
Nitrobenzene
4-Nitrobiphenyl
4-Nitrophenol
2-Nitropropane
N-Nitroso-N-methylurea
N-Nitrosodimethylamine
N-Nitrosmorpholine
Parathione
82688
87865
108952
106503
75445
7803512
7723140
85449
1336363
1120714
57578
123386
114261
78875
75569
75558
91225
106514
100425
96093
1746016
79345
127184
7550450
108883
95807
584849
95534
8001352
120821
79005
79016
959540
880620
1214480
15820980
5408410
1080540
5936020
750140
753540
13302070
954760
1083830
1064230
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Pentachloronitrobenzene (quintoben-
zene)
Pentachlorophenol
Phenol
p-Phenylenediamine
Phosgene
Phosphine
Phosphorus
Phthalic anhydride
Polychlorinated biphenyls (Aroclors)
1,3-Propane sultone
3-Propiolactone
Propionaldehyde
Propoxur(baygon)
Propylene dichroride (1,2-dichloro-
propane)
Propylene oxide
1,2-Propylenimine (2-methyl aziridine)
Quinoline
Quinone
Styrene
Styrene oxide
2,3,7,8-Tetrachlorodibenzo-p-dioxin
1,1,2 2-Tetrachloroethane
Tetrachloroethylene (perchloroethyl-
ene)
Titanium tetrachloride
Toluene
2,4-Toluene diamine
2,4-Toluene diisocyate
o-Toluidine
Toxaphene (chlorinated camphene)
1,2,4-Trichlorobenzene
1,1,2-Trichlorethane
Trichloroethylene
2,4,5-Trichlorophenol
2,4,6-Trichlorophenol
Triethylamine
Trifluralin
2,2,4-Trimethylpentane
Vinyl acetate
Vinyl bromide
Vinyl chloride
Vinylidene chloride (1,1-dichloroethyl-
ene)
Xylenes (isomers and mixtures)
o-Xylene
m-Xylene
p-Xylene
Antimony compounds
Arsenic compounds (inorganic including
arsine)
Beryllium compounds
Cadmium compounds
Chromium compounds
Cobalt compounds
Coke oven emissions
Cyanide compounds
Glycol ethers
Lead compounds
Manganese compounds
Mercury compounds
Fine mineral fibers
Nickel compounds
Polycyclic organic matter
Radionuclides (including radon)
Selenium compounds
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Table 2. NTP studies of the Clean AirAct airtoxics.
Route of administration
Inhalation Other Chemical Genetic Organ systems
Subchronica Chronic Subchronica Chronic disposition toxicity toxicity
12 20 23 66 61 195 92
"Limited to chemicals that did not have subsequent chronic studies performed.
and are one ofthe primary lesions induced
in cells exposed to these metals. Costa et al.
(8,9) have evaluated the feasibility ofusing
a DNA-protein cross-link assay in periph-
eral white blood cells to detect human
exposure to both chromium and nickel
compounds in occupational settings. Their
results showed an elevation in this bio-
marker related to chromium and nickel
exposures, verifying its usefulness as a bio-
marker of exposure. Ifone presumes that
target tissues such as the lung also have
these types oflesions, then this assay might
also serve as an early warning ofpotential
disease development.
These are but two examples ofsome of
the work emerging in the field ofbiomarker
research. The availability ofthese and other
biomarkers will help measure individual
exposures, define mechanisms and path-
ways in disease causation and establish
whether these pathways are common to
both animals and humans.
Future Use of Biomarkers in
Risk Assessment
The value ofbiomarker research can only
be realized when it is used in prevention
and intervention strategies that protect
public health. Focusing on human health
needs leads to four overarching areas of
biomarker use.
First there is a need for biomarkers that
can be used in the risk assessment arena to
enhance extrapolation from animal data to
human exposure situations. These would
be biomarkers that reveal common mecha-
nistic pathways relevant to toxicity in both
humans and animals and could ideally be
an integrated measure of events occurring
over time. Biomarkers that can account for
individual variability or susceptibility
would also be useful components for
extrapolation schemes.
Second, we must remember that
human health is affected by many different
diseases, of which cancer is only one.
Important disease end points to consider
include pulmonary dysfunction, immune
dysfunction, and birth defects. Biomarkers
for these and other noncancer end points
will be a critical need in the future.
Third, human health can best be
protected when intervention and treatment
strategies are employed prior to clinical
expression of a disease. Developing
biomarkers that serve as early warning signs
to detect intermediate effects would greatly
enhance our ability to design successful,
cost-effective public health strategies.
These biomarkers could be chemical,
pathological, or functional in nature.
Lastly, biomarkers could be employed
in an evaluative capacity. They could
assess the efficacy of prevention and inter-
vention strategies, both in clinical and reg-
ulatory settings. This latter evaluative
component could help ensure that dollars
spent protecting public health do, in fact,
achieve the desired outcome. This results-
or outcome-oriented use ofbiomarkers, if
successful, would greatly enhance regula-
tory agencies' ability to assess the relevance
oftheir programs.
This view of the future must be tem-
pered with an understanding ofthe ethical
considerations ofbiomarker use. Biomarkers
ofexposure, ofinternal dose, and ofbiologi-
cally effective doses will be oftremendous
benefit in regulating human exposures and
protecting public health. More problem-
atic, however, are biomarkers that indicate
altered structure or function, the presence
ofclinical disease, or enhanced susceptibil-
ity to toxic compounds. Information from
these biomarkers could potentially be used
to deny access to jobs or insurance. The
social and ethical problems surrounding the
use ofbiomarkers and susceptibility infor-
mation need to be anticipated and rational
schemes devised to circumvent misuse of
this promising technology.
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